Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Jan 24, 2023
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apellis Pharmaceuticals, Inc.
| -1.41K |
$52.05 | -$73,494.60 | -5.66% | 23.56K |
Jan 20
| |||||||
Apellis Pharmaceuticals, Inc.
| -130.00 |
$58.41 | -$7,593.30 | -0.52% | 24.84K |
Oct 26
| |||||||
Apellis Pharmaceuticals, Inc.
| -2.70K |
$45.00 | -$121,410.00 | -9.75% | 24.97K |
Jun 17
| |||||||
Apellis Pharmaceuticals, Inc.
| -82.00 |
$49.28 | -$4,040.96 | -0.29% | 28.32K |
Mar 25
| |||||||
Apellis Pharmaceuticals, Inc.
| -175.00 |
$47.12 | -$8,246.00 | -0.61% | 28.41K |
Feb 10
| |||||||
Apellis Pharmaceuticals, Inc.
| -434.00 |
$38.59 | -$16,748.06 | -1.50% | 28.58K |
Jan 28
| |||||||
Apellis Pharmaceuticals, Inc.
| 17.47K |
—
|
—
| +151.22% | 29.02K |
Jan 21
| |||||||
Apellis Pharmaceuticals, Inc.
| 882 |
—
|
—
| +8.37% | 11.42K |
Oct 26
| |||||||
Apellis Pharmaceuticals, Inc.
| -82.00 |
$41.16 | -$3,375.12 | -0.82% | 9.95K |
Mar 25
| |||||||
Apellis Pharmaceuticals, Inc.
| 1.25K |
—
|
—
| +14.23% | 10.03K |
Mar 1
| |||||||
Apellis Pharmaceuticals, Inc.
| -144.00 |
$47.72 | -$6,871.68 | -1.61% | 8.78K |
Feb 10
| |||||||
Apellis Pharmaceuticals, Inc.
| 5K |
—
|
—
| +127.29% | 8.93K |
Jan 28
| |||||||
Apellis Pharmaceuticals, Inc.
|
0
|
$26.99 | -$192,240.00 |
—
| 3.61K |
Oct 7
| |||||||
Apellis Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||